N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=147 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Adult Angiosarcoma · Adult Epithelioid Sarcoma · Adult Leiomyosarcoma
Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=72 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Myxofibrosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Leiomyosarcoma
Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…
Phase 2 N=20 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants
Phase 2 N=53 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Adult Malignant Fibrous Histiocytoma of Bone · Desmoid Tumor · Endometrial Cancer
Primary: Overall Objective Response — 1; 21; 26 participants
Phase 2 N=20 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Metastatic Leiomyosarcoma
Primary: Response Rate (Per RECIST 1.1) — 1 Participants
Phase 2 N=80 Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Sarcoma
Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants
Phase 2 N=37 Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Phase 2 N=16 Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Metastatic Soft Tissue Sarcoma
Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562
Phase 2 N=48 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Phase 2 N=113 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) · Rhabdomyosarcoma · Leiomyosarcoma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Phase 2 N=129 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Sarcoma
Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants
Phase 2 N=164 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
Locally Advanced Bone Sarcoma · Locally Advanced Dedifferentiated Liposarcoma · Locally Advanced Gastrointestinal Stromal Tumor
Primary: Number of Participants Who Achieved a Confirmed Response — 2; 6; 1; 2 Participants
Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Phase 2 N=12 Alimta Plus Gemcitabine for Advanced Sarcoma
Sarcoma, Soft Tissue
Primary: Tumor Best Response Rate — 0 Participants
Phase 2 N=25 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Phase 2 N=42 A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Metastatic Sarcoma
Primary: Disease Control Rate — 13; 2; 3 Participants
Phase 2 N=20 Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Pleomorphic Rhabdomyosarcoma · Stage IIB Adult Soft Tissue Sarcoma AJCC v7 · Stage III Adult Soft Tissue Sarcoma AJCC v7
Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months
Phase 2 N=58 A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma · Stage IV Adult Soft Tissue Sarcoma
Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=131 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Liposarcoma · Osteogenic Sarcoma · Ewing/Ewing-like Sarcoma
Primary: Progression-free Survival (PFS). Cohort A and Cohort B — 1.87; 2.07; 3.6; 1.7 months
N/A N=274 A Public Health Intervention Program to Improve the Initial Management of Soft Tissue Sarcomas.
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
Phase 2 N=14 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Adult Synovial Sarcoma · Recurrent Adult Soft Tissue Sarcoma · Stage III Adult Soft Tissue Sarcoma
Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants
Phase 2 N=10 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases
Synovial Sarcoma · Single or Multiple Lung Metastases
Primary: Number of Participants Evaluated for Toxicity — 10 Participants
Phase 2 N=20 Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Soft-tissue Sarcomas
Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2